Allarity presents cancer drug data at AACR conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
April 21, 2026 8:01 AM EDTÂ Â Â Â Â Â Â Â
The Stenoparib-DRP® companion diagnostic is associated with enhanced overall survival in Ovarian Cancer patients
Posters now available on Allaritys website
TARPON SPRINGS, Fla., April 21, 2026 Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing... More
